Vimarsana
Biggest News Aggregation in the World

Mahima Datla News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mahima Datla. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mahima Datla Today - Breaking & Trending Today

Krishna Ella new President of Indian Vaccine Manufacturers' Association - Vimarsana News

Krishna Ella new President of Indian Vaccine Manufacturers' Association

The Indian Vaccine Manufacturers Association (IVMA) on Monday announced Bharat Biotech Co-Founder and Executive Chairman Dr. Krishna M Ella will be its new President for a two-year period.A distinguished scientist and successful entrepreneur, ...

Dr. Krishna Ella is new president of IVMA - Vimarsana News

Dr. Krishna Ella is new president of IVMA

Hyderabad: The Indian Vaccine Manufacturers Association (IVMA) has announced Dr. Krishna M Ella, a distinguished scientist and successful entrepreneur, as

Source: siasat.com
Dr Krishna Ella takes charge as president of Indian Vaccine Manufacturers Association - Vimarsana News

Dr Krishna Ella takes charge as president of Indian Vaccine Manufacturers Association

Dr. Ella takes over the presidency from Adar C Poonawala, who held the post from 2019 to 2024.

Meet Telangana's richest woman with net worth Rs 8700 crore, her business is... - Vimarsana News

Meet Telangana's richest woman with net worth Rs 8700 crore, her business is...

As a third-generation leader, Mahima has steered significant advancements in the vaccine sector.

Dengue vaccine India: Takeda, Biological E enter manufacturing pact to produce 50 million doses of Dengue vaccine - Vimarsana News

Dengue vaccine India: Takeda, Biological E enter manufacturing pact to produce 50 million doses of Dengue vaccine

Japanese drug giant Takeda has partnered with Indian vaccine maker Biological E (BE) to manufacture its Dengue vaccine. BE will increase its manufacturing capacity to up to 50 million doses a year, supporting Takeda's goal to produce 100 million doses annually by 2030. The collaboration leverages Takeda's existing facility in Germany and its partnership with IDT Biologika GmbH.